Table 1.
Comparative clinical characteristics of the PUC and TCGA-OV cohorts.
| Variable | PUC Cohort |
TCGA-OV Cohort |
p-Value |
|---|---|---|---|
| n sample (n with imaging) | 123 (104) | n = 415 (97) | |
| Age (mean ± SD) | 59 ± 11.6 | 59 ± 11.5 | 0.98 |
| (min–max; range) | (29–83; 54) | (26–87; 61) | |
| Stage | 0.67 | ||
| III (%) | 105 (85.4) | 345 (83.1) | |
| IV (%) | 18 (14.6) | 70 (16.9) | |
|
Adiposity Estimates VAT (cm2) |
118.1 ± 58.9 | 130.8 ± 70 | 0.91 |
| VAT/SCAT | 0.49 ± 0.22 | 0.50 ± 0.22 | 0.55 |
| VAT/TAT | 0.32 ± 0.09 | 0.32 ± 0.09 | 0.55 |
| WBAT (kg) | 27.3 ± 9.2 | 30 ± 11.7 | 0.96 |
| Liver Steatosis (CTl-s) | 0.015 | ||
| Normal | 85 (81.9) | 65 (67) | |
| Steatosis | 19 (18.1) | 32 (33) | |
| Type of Surgery * | |||
| Upfront surgery | 63 (51.2) | 414 (99.8) | |
| Interval surgery | 46 (37.4) | 1 (0.2) | |
| Never surgery # | 14 (11.4) | N/A | |
| Residual Disease * | <0.0001 | ||
| Microscopic | 55 (44.7) | 86(20.7) | |
| Else residual disease | 68 (55.3) | 329 (79.3) | |
| Type of Response | 0.52 | ||
| Complete | 76 (61.8) | 286 (68.9) | |
| Partial/Stable | 35 (28.5) | 90 (21.7) | |
| Progressive | 12 (9.8) | 39 (9.4) | |
| Statin/Metformin Use | 31 (25.2) | N/A | |
| Mean/Median FU (months) | 58.9/44 | 44.5/38.3 | <0.0001 |
| (min-max; range) | (1–263; 262) | (1–183; 182) | |
| Deaths (%) | 98 (79.7) | 263 (63.4) | 0.0005 |
N/A (not available). * Only patients with information on debulking status (reported in the surgical protocol) or a residual tumor (assessed by CT imaging after completion of treatment) were included. # inoperable cases based on extensive disease and/or severe co-morbidities.